Bernstein Harold 4

4 · Maze Therapeutics, Inc. · Filed Mar 20, 2026

AI-generated summary of this filing

Updated Mar 20, 2026

Maze (MAZE) CMO Harold Bernstein Exercises Options, Sells Shares

What Happened

Harold Bernstein, President of R&D and Chief Medical Officer at Maze Therapeutics, exercised options and sold company stock on March 20, 2026. The filing shows he acquired 15,000 shares by exercising/options conversion at $10.42 per share (cost $156,300) and sold a total of 15,000 shares in three open‑market transactions for aggregate proceeds of $736,440. The Form 4 also reports a separate derivative conversion/settlement of 15,000 shares shown with a $0.00 price and $0 proceeds.

Key Details

Date of transactions: March 20, 2026.
Exercise/acquisition: 15,000 shares at $10.42 each — $156,300 total.
Sales (open market), weighted average prices and proceeds:
- 6,161 shares at $48.20 (weighted) — $296,977 (prices ranged $47.77–$48.75).
- 3,795 shares at $49.32 (weighted) — $187,169 (prices ranged $48.78–$49.77).
- 5,044 shares at $50.02 (weighted) — $252,294 (prices ranged $49.79–$50.52).
- Total reported sales proceeds: $736,440.
Additional derivative entry: 15,000 shares reported as exercised/converted and disposed at $0.00 (no cash proceeds reported).
Plan/footnotes: Transactions were effected under a Rule 10b5‑1 trading plan adopted Sept 29, 2025. The filing includes weighted‑average price ranges and a vesting schedule note for the underlying award.
Shares owned after the transaction: Not disclosed in the provided excerpt of the Form 4.
Timeliness: Filing date and report period are both Mar 20, 2026 — appears timely (not marked late).

Context

This filing shows an exercise of options and same‑day market sales of the same number of shares — a common pattern when executives exercise stock options and sell shares to cover costs or diversify. The separate $0.00 derivative entry likely reflects internal conversion/settlement mechanics reported on the Form 4 (not a cash sale).
The trades were executed under a pre‑arranged 10b5‑1 plan, which is intended to permit scheduled trading regardless of later company developments; such plans are common and reduce the likelihood that these individual sales signal new insider sentiment.

Form 4

Period: 2026-03-20

President, R&D & CMO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-20$10.42/sh+15,000$156,300→ 15,000 total
Sale
Common Stock
[F1][F2]
2026-03-20$48.20/sh−6,161$296,977→ 8,839 total
Sale
Common Stock
[F1][F3]
2026-03-20$49.32/sh−3,795$187,169→ 5,044 total
Sale
Common Stock
[F1][F4]
2026-03-20$50.02/sh−5,044$252,294→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]
2026-03-20−15,000→ 252,407 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (15,000 underlying)

Footnotes (5)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.77 to $48.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.78 to $49.77 per share, inclusive.
[F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.79 to $50.52 per share, inclusive.
[F5]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-03-20

1 file